Effect of Different Concentrations of Xylitol and Erythritol on Gut Peptide Release and Gastric Emptying in Humans
NCT ID: NCT03039478
Last Updated: 2018-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2017-02-24
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers
NCT02824614
Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans
NCT02563847
Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion
NCT00978900
Effects of Oral Xylitol on Subsequent Energy Intake
NCT05671965
Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers
NCT02821923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Xylitol 7g in 300mL tap water
12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
Xylitol 7g
Xylitol 7g in 300mL tap water
Xylitol 17g in 300mL tap water
12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
Xylitol 17g
Xylitol 17g in 300mL tap water
Xylitol 35g in 300mL tap water
12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
Xylitol 35g
Xylitol 35g in 300mL tap water
Erythritol 10g in 300mL tap water
12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
Erythritol 10g
Erythritol 10g in 300mL tap water
Erythritol 25g in 300mL tap water
12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
Erythritol 25g
Erythritol 25g in 300mL tap water
Erythritol 50g in 300mL tap water
12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
Erythritol 50g
Erythritol 50g in 300mL tap water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xylitol 7g
Xylitol 7g in 300mL tap water
Erythritol 10g
Erythritol 10g in 300mL tap water
Xylitol 17g
Xylitol 17g in 300mL tap water
Xylitol 35g
Xylitol 35g in 300mL tap water
Erythritol 25g
Erythritol 25g in 300mL tap water
Erythritol 50g
Erythritol 50g in 300mL tap water
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)
* Age 18-40 years
* Stable body weight for at least three months
* Informed Consent as documented by signature
Exclusion Criteria
* Regular intake of medications (except for oral contraceptives)
* Evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic, gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other diseases at screening
* Clinically relevant abnormalities in haematological laboratory parameters
* Food allergies, food intolerance
* Pregnancy
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Beglinger, Prof
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PolyDose
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.